Abstract
Background Myocardial infarction (MI) is the main cause of global mortality and morbidity despite the development of therapeutic approaches. ShenZhuGuanXin granules (SG) have been shown to possess cardioprotective effects against coronary heart disease (CHD). However, little is known about its specific mechanism. The present study aimed to investigate the therapeutic effect of SG in cardiac dysfunction and to demonstrate whether SG can promote myocardium angiogenesis by establishing a rat model of myocardial infarction with left anterior descending ligating. Methods and Results Three days after MI, rats were randomly divided into six groups: sham group (sham), MI group (MI), MI + low dose SG (SG-L) group, MI + middle dose SG (SG-M) group, MI + high dose SG (SG-H) group, and MI + compound Danshen dropping pills (CDDP) group as a positive control. Four weeks after administration, rats underwent hemodynamics and echocardiography study. Ventricle tissues were processed for histology and immunohistochemistry studies. Compared with MI group, SG treatment dose-dependently improved cardiac hemodynamic function, attenuated infarct size, increased microvessel density, and increased the expression of PECAM-1/CD31 and VEGF. Conclusions SG dose-dependently improved cardiac hemodynamic function and attenuated infarct size by promoting angiogenesis through upregulating PECAM-1/CD31 and VEGF expression.
Highlights
Studies surrounding the prognosis of myocardial infarction (MI) had become one of the most heated topics in the field of life sciences
The mortality of Myocardial infarction (MI) is significantly lower than it used to be with the development of therapeutic approaches [1,2,3], there remains the need for further deep study on related factors that contributed to prognosis of myocardial infarction and novel therapeutic agents
MI caused a significant decrease in left ventricular systolic pressure (LVSP) and +dP/dt.max when compared with the sham group (LVSP: 116.83 ± 9.00 versus 89.80 ± 6.76 mmHg, P < 0.05; +dP/dt.max 2724.27 ± 321.84 versus 1331.23 ± 116.49 mmHg/s, P < 0.05)
Summary
Studies surrounding the prognosis of myocardial infarction (MI) had become one of the most heated topics in the field of life sciences. China has expended great efforts in developing and inheriting Tradition Chinese Medicine (TCM) for treatment of coronary heart disease (CHD). The present study aimed to investigate the therapeutic effect of SG in cardiac dysfunction and to demonstrate whether SG can promote myocardium angiogenesis by establishing a rat model of myocardial infarction with left anterior descending ligating. Compared with MI group, SG treatment dose-dependently improved cardiac hemodynamic function, attenuated infarct size, increased microvessel density, and increased the expression of PECAM-1/CD31 and VEGF. SG dose-dependently improved cardiac hemodynamic function and attenuated infarct size by promoting angiogenesis through upregulating PECAM-1/CD31 and VEGF expression
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
